Clinical Trial · NCT02673151

68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment

Overview

The purpose of this research study is to see if recurrent prostate cancer can be identified using a special procedure called a positron emission tomography (PET) scan. PET/CT is used to describe information regarding the function, as well as location and size of a tumor.

Sponsor

Stanford University

Phase

Phase 2/3

Contacts

Andrei Iagaru, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02673151

Drug / Compound

PSMA-11

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Chelator: HBED-CC

Linker: Ahx

Eligibility

Inclusion

A rise of PSA measurement of 2 or more ng/mL over the nadir
Able to provide written consent
Karnofsky performance status of ≥ 50 (or Eastern Cooperative Oncology Group \[ECOG\] / World Health Organization \[WHO\] equivalent)
Post-radiation therapy -American Society for Radiation Oncology (ASTRO)-Phoenix consensus definition
Confirmatory persistent PSA greater than 0.2 ng/mL (total of two PSA measurements greater than 0.2 ng/mL)
PSA greater than 0.2 ng/mL measured 6 to 13 weeks after RP
Rising prostate-specific antigen (PSA) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy)
Histopathological proven prostate adenocarcinoma
Post radical prostatectomy (RP) - American Urology Association (AUA) recommendation

Exclusion

Investigational therapy for prostate cancer.
Unable to lie flat, still or tolerate a positron emission tomograpy (PET) scan.